Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Initiates Coverage On Senti Biosciences with Neutral Rating

JP Morgan Initiates Coverage On Senti Biosciences with Neutral Rating

JP Morgan analyst Brian Cheng initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Neutral rating.

byBenzinga Newsdesk

December 16, 2022

1 minute read

JP Morgan analyst Brian Cheng initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Neutral rating.

Barclays Maintains Overweight on SLB, Raises Price Target to $74

By Benzinga Newsdesk

January 26, 8:49 AM

Barclays analyst David Anderson maintains SLB (NYSE:SLB) with a Overweight and raises the price target from $62 to $74.

SLB

Stephens & Co. Initiates Coverage On BJ’s Restaurants with Equal-Weight Rating, Announces Price Target of $27

By Benzinga Newsdesk

September 23, 6:59 AM

Stephens & Co. analyst Joshua Long initiates coverage on BJ's Restaurants (NASDAQ:BJRI) with a Equal-Weight rating and announces Price Target of $27.

BJRI

Will The S&P 500 Finish Higher In 2022? Here’s What Analysts Predict

By Shanthi Rexaline

July 10, 1:43 PM

The equity markets went through a harrowing time in the first-half of 2022, but Wall Street analysts are confident of an improvement for the remainder of the year.

SPY

Movers
News

What Happened With Caltalent Stock?

By Ryan Gustafson

December 19, 5:12 PM

Catalent, Inc. (NYSE: CTLT) shares traded higher on Tuesday. Following losses at the end of October, the stock has rebounded over the past month.

CTLT

JP Morgan Initiates Coverage On Senti Biosciences with Neutral Rating

Related Posts

Barclays Maintains Overweight on SLB, Raises Price Target to $74

Stephens & Co. Initiates Coverage On BJ’s Restaurants with Equal-Weight Rating, Announces Price Target of $27

Will The S&P 500 Finish Higher In 2022? Here’s What Analysts Predict

What Happened With Caltalent Stock?